4:40 PM
Jun 22, 2017
 |  BC Extra  |  Clinical News

Editas, Church further dispute CRISPR off-target report

In response to a letter published in Nature Methods last month that found a high level of off-target mutations in mice treated with CRISPR/Cas9, executives at Editas Medicine Inc. (NASDAQ:EDIT) along with academic CRISPR expert and company advisor George Church published a rebuttal on the preprint server bioRxiv in which they reanalyzed the data and concluded natural genetic variations prior to CRISPR treatment were the likely cause of variants.

In a letter published...

Read the full 358 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >